Borges LJS, Mares OAR, Barón CJL, Ochoa PV, Castaño GRJ, Ayala HE

Language: Spanish
References: 6
Page: 1-3
PDF size: 639.23 Kb.

ABSTRACT

The hypertrophic cardiomyopathy (HCM) is a hereditary disease defined as an increase in the wall thickness in one or more myocardial segments in the absent of any other cardiac, systemic or metabolic condition that may justify this disease. It is of autosomal dominant transmission due to mutations in various cardiac sarcomere protein genes. HCM is divided into obstructive and non-obstructive. The former includes the mid-ventricular variant, a rare form of presentation that could be accompanied or not by apical aneurysm, ventricular arrhythmia, and sudden death. It is described the case of a 54-year-old male patient, with an evident obstructive HCM, mid-ventricular variant, associated to Markis type I coronary ectasia, myocardial bridging in the middle distal segment of the anterior descending artery, in which the physical exam and the imaging studies played an important role for the diagnosis.

REFERENCES

1. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020 [acceso 20/11/2020];142(25):e558-e631. Disponible en: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/11/18/18/47/2020-aha-acc-guideline-for-hcm-gl-hcm

2. Penas M, Mosquera I, Bouzas B, Vázquez J, Castro A. El electrocardiograma en la miocardiopatía hipertrófica apical. Presentación de un caso con manifestaciones únicas. Rev Esp Cardiol. 1999 [acceso 13/11/2021];52:1148-50. Disponible en: https://www.revespcardiol.org/en-el-electrocardiogramamiocardiopatia-hipertrofica-apical--articulo-X0300893299000135?redirect=true

3. Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica. Artículo especial. Rev Esp Cardiol. 2015 [acceso 14/10/2021];68(1):63.e1-e52. Disponible en: https://www.revespcardiol.org/es-guia-practica-clinica-esc-2014-articulo-S0300893214006204

4. Peña M, Palomino J, Ochoa J, Barriales R. Diagnóstico y tratamiento de la miocardiopatía hipertrófica: comparación de las guías europeas y americanas. Cardiocore. 2015 [acceso 02/03/2022];50(2):76-9. Disponible en: https://www.elsevier.es/es-revista-cardiocore-298-articulo-diagnostico-tratamiento-miocardiopatia-hipertrofica-comparacion-S1889898X14001248

5. Spertus JA, Fine JT, Elliott P, Ho C, Olivotto, I, Saberi S, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467-75. DOI: https://doi.org/10.1016/S0140-6736(21)00763-7

6. Zhai SS, Fan CM, An SY, Hang F, Yang YJ, Yan LR, et al. Clinical Outcomes of Myocardial Bridging versus No Myocardial Bridging in Patients with Apical Hypertrophic Cardiomyopathy. Cardiology.2018;139(3):161-8. DOI: https://doi.org/10.1159/000486276